Denosumab Reduces Fracture Incidence in Postmenopausal Women, Leuven University Study  
3/31/2011 10:47:17 AM

Elsevier -- Denosumab reduced the incidence of new vertebral and hip fractures in postmenopausal women with osteoporosis at both higher and lower risk for fracture, in a post-hoc analysis of data from a 3-year, phase III randomized trial in the Journal of Clinical Endocrinology & Metabolism.